Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma

被引:2
|
作者
Bajestani, Nojan [1 ]
Wu, Gavin [1 ]
Hussein, Ahmed [1 ]
Makary, Mina S. [2 ]
机构
[1] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, Dept Radiol, Div Vasc & Intervent Radiol, 395 W 12th Ave, Columbus, OH 43210 USA
关键词
hepatocellular carcinoma; locoregional therapy; immunotherapy; combination therapy; progression-free survival; overall survival; PERCUTANEOUS RADIOFREQUENCY ABLATION; INTERNAL RADIATION-THERAPY; RANDOMIZED CONTROLLED-TRIAL; TRANSARTERIAL CHEMOEMBOLIZATION; OPEN-LABEL; PHASE-III; SURGICAL RESECTION; MICROWAVE ABLATION; Y-90; MICROSPHERES; SYSTEMIC THERAPY;
D O I
10.3390/biomedicines12071432
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
More than 800,000 people worldwide are diagnosed with HCC (hepatocellular carcinoma) each year, with approximately 700,000 deaths alone occurring in that same year. Treatment of HCC presents complex therapeutic challenges, particularly in intermediate and advanced stages. LRTs such as transarterial chemoembolization (TACE) and ablations have been the mainstay treatment for early to intermediate-stage HCC, and systemic therapies are used to treat intermediate-late-stage HCC. However, novel literature describing combining LRT with systemic therapies has shown promising results. This review explores recent advances in both liver-directed techniques for hepatocellular carcinoma, including bland transarterial embolization, chemoembolization, radioembolization, and ablative therapies in conjunction as well as with systemic therapies, with a focus on combination therapies, patient selection, procedural technique, periprocedural management, and outcomes. Our findings suggest that LRT combined with systemic therapies is a viable strategy for improving progression-free survival and time to progression for patients with intermediate-to-late-stage HCC. However, further investigation is required to refine treatment protocols and define patient cohorts that would benefit the most.
引用
收藏
页数:30
相关论文
共 50 条
  • [1] Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy附视频
    Jian Xue
    Hongbo Ni
    Fan Wang
    Ke Xu
    Meng Niu
    Journal of Interventional Medicine, 2021, (03) : 105 - 113
  • [2] Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions
    Dendy, Meaghan S.
    Ludwig, Johannes M.
    Stein, Stacey M.
    Kim, Hyun S.
    LIVER CANCER, 2019, 8 (05) : 326 - 340
  • [3] Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma
    Chiang, Chi Leung
    Chan, Kenneth Sik Kwan
    Chiu, Keith Wan Hang
    Lee, Francis Ann Shing
    Chen, Wenqi
    Wong, Natalie Sean Man
    Ho, Ryan Lok Man
    Lee, Venus Wan Yan
    Man, Kwan
    Kong, Feng Ming
    Chan, Albert Chi Yan
    JAMA ONCOLOGY, 2024, 10 (11) : 1548 - 1553
  • [4] Clinical Safety and Efficacy of Locoregional Therapy Combined with Adoptive Transfer of Allogeneic γδ T Cells for Advanced Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
    Zhang, Tingting
    Chen, Jibing
    Niu, Lizhi
    Liu, Yu
    Ye, Guangbin
    Jiang, Minli
    Qi, Zhongquan
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2022, 33 (01) : 19 - +
  • [5] Locoregional Therapy for Hepatocellular Carcinoma
    Kudo, M.
    LIVER CANCER, 2015, 4 (03) : 163 - 164
  • [6] Locoregional Therapy for Hepatocellular Carcinoma
    Guimaraes, Marcelo
    Uflacker, Renan
    CLINICS IN LIVER DISEASE, 2011, 15 (02) : 395 - +
  • [7] Locoregional Therapy of Hepatocellular Carcinoma
    Habib, Ali
    Desai, Kush
    Hickey, Ryan
    Thornburg, Bartley
    Lewandowski, Robert
    Salem, Riad
    CLINICS IN LIVER DISEASE, 2015, 19 (02) : 401 - +
  • [8] Impact of prior locoregional therapy on immunotherapy response in patients with advanced hepatocellular carcinoma
    Batkhurel, Khaliun
    Gan, Lay Theng
    Gibson, Robert
    Loewenthal, Mark
    Tjang, Randy
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 138 - 139
  • [9] Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma
    Gu, Huiying
    Li, Jing
    You, Nan
    Wu, Ke
    Wang, Zheng
    Wang, Liang
    Zhu, Yinan
    Liu, Qinqin
    Peng, Xuehui
    Zheng, Lu
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (24)
  • [10] Combined versus single locoregional therapy in the treatment of unresectable hepatocellular carcinoma
    Othman, Moustafa H. M.
    Mourad, Amr F.
    Abd Ellah, Mohamed M. H.
    Imam, Hala M. K.
    EGYPTIAN JOURNAL OF RADIOLOGY AND NUCLEAR MEDICINE, 2014, 45 (02): : 395 - 401